Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Glucagon
Therapeutic Area : Endocrinology
Study Phase : Approved
Sponsor : Arecor
Deal Size : Undisclosed
Deal Type : Agreement
Tetris Pharma Signs Service Agreement With Syneos Health
Details : Ogluo® is a ready-to-use, ambiently stored, preparation of glucagon that has been specifically designed for patients living with diabetes with severe hypoglycaemia.
Brand Name : Ogluo
Molecule Type : Peptide
Upfront Cash : Undisclosed
December 12, 2022
Lead Product(s) : Glucagon
Therapeutic Area : Endocrinology
Highest Development Status : Approved
Sponsor : Arecor
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Glucagon
Therapeutic Area : Endocrinology
Study Phase : Approved
Sponsor : Arecor
Deal Size : Undisclosed
Deal Type : Acquisition
Xeris’ Commercialization Partner for Ogluo, Tetris Pharma Ltd, to Be Acquired by Arecor Therapeutics
Details : Under the terms of the proposed acquisition, Arecor Therapeutics has agreed to acquire Tetris Pharma and will continue to commercialize Ogluo in the UK and EEA. Gvoke® (US) /Ogluo® (EU), the first prescription, ready-to-use, pre-mixed, pre-measured glu...
Brand Name : Ogluo
Molecule Type : Peptide
Upfront Cash : Undisclosed
August 01, 2022
Lead Product(s) : Glucagon
Therapeutic Area : Endocrinology
Highest Development Status : Approved
Sponsor : Arecor
Deal Size : Undisclosed
Deal Type : Acquisition
LOOKING FOR A SUPPLIER?